AGL 38.18 Decreased By ▼ -0.22 (-0.57%)
AIRLINK 142.98 Increased By ▲ 7.98 (5.91%)
BOP 5.07 Decreased By ▼ -0.02 (-0.39%)
CNERGY 3.77 Decreased By ▼ -0.02 (-0.53%)
DCL 7.56 Decreased By ▼ -0.03 (-0.4%)
DFML 44.48 Increased By ▲ 0.03 (0.07%)
DGKC 76.25 Decreased By ▼ -1.15 (-1.49%)
FCCL 26.95 Increased By ▲ 0.07 (0.26%)
FFBL 52.00 Decreased By ▼ -0.97 (-1.83%)
FFL 8.52 Decreased By ▼ -0.02 (-0.23%)
HUBC 125.51 Increased By ▲ 1.71 (1.38%)
HUMNL 9.99 Increased By ▲ 0.05 (0.5%)
KEL 3.74 Increased By ▲ 0.01 (0.27%)
KOSM 8.15 Increased By ▲ 0.07 (0.87%)
MLCF 34.75 Increased By ▲ 1.05 (3.12%)
NBP 58.71 Increased By ▲ 0.22 (0.38%)
OGDC 154.50 Increased By ▲ 4.55 (3.03%)
PAEL 25.15 Increased By ▲ 0.45 (1.82%)
PIBTL 5.93 Increased By ▲ 0.08 (1.37%)
PPL 118.31 Increased By ▲ 6.66 (5.97%)
PRL 24.38 Increased By ▲ 0.48 (2.01%)
PTC 12.00 Decreased By ▼ -0.10 (-0.83%)
SEARL 56.00 Decreased By ▼ -0.89 (-1.56%)
TELE 7.05 Increased By ▲ 0.05 (0.71%)
TOMCL 34.99 Decreased By ▼ -0.16 (-0.46%)
TPLP 6.98 Decreased By ▼ -0.07 (-0.99%)
TREET 13.98 Decreased By ▼ -0.18 (-1.27%)
TRG 46.10 Decreased By ▼ -0.13 (-0.28%)
UNITY 26.00 Decreased By ▼ -0.08 (-0.31%)
WTL 1.21 No Change ▼ 0.00 (0%)
BR100 8,822 Increased By 86.7 (0.99%)
BR30 26,723 Increased By 466.7 (1.78%)
KSE100 83,532 Increased By 810.2 (0.98%)
KSE30 26,710 Increased By 328 (1.24%)

KARACHI: The pharmaceutical sector in Pakistan is facing significant challenges, with only four foreign companies now left maintaining manufacturing facilities in the country.

Ayesha T. Haq, Executive Director of Pharma Bureau, highlighted the issues hindering the growth of foreign pharmaceutical companies in Pakistan.

“The regulatory environment in Pakistan is a major obstacle to the growth of foreign pharmaceutical companies,” Haq said. “The DRAP Act 2012, Drugs Act 1976, and Drug Pricing Policy 2018 contain numerous anomalies, including overlapping powers, unclear standard operating procedures, and irrational pricing of essential drugs. These issues have led to a lack of confidence among foreign investors.”

Experts say Pakistan budget massively negative for struggling healthcare sector

Haq cited that over 30 multinational companies (MNCs) have come to Pakistan market over the course of history but in recent decades, they have been reduced to just four, which is evidence of the sector’s struggles.

“The primary reasons for their disinvestment include an onerous tax regime, regulatory challenges, economic instability, pricing controls, and counterfeit medicines,” she explained. “Price controls have made it economically unviable for MNCs to continue operations in Pakistan, leading to reduced margins and losses.”

Haq emphasised that the current pricing policy is unsustainable and has resulted in companies making losses on many low-priced drugs.

“No company can afford to run at a loss,” she said. “This also destroys investors’ confidence, and companies are not inclined to incur further losses and introduce new therapies into the Pakistani market.”

Many experts see the lack of investment as not only leading to lower dollar inflow crucial for the debt-ridden economy — but also hindering the growth of research and development in the pharmaceutical sector that employs skilled labour and pours back into career development of Pakistani nationals.

Pakistan’s pharma sector can increase exports to $3bn in five years, but it ‘needs policy, govt support’

The exit of MNCs also carries a negative perception, hindering the potential of other sectors when seen in the light of Pakistan being a potential market for foreign companies.

The Pharma Bureau is advocating for policy changes, including rational and independent pricing of essential drugs, elimination of taxation anomalies, and removal of anti-investment policies. Haq also stressed the need for regulatory reforms, including empowering DRAP to achieve international certifications and eradicate counterfeit medicines.

“The government needs to create a conducive business environment to attract and retain foreign investment,” Haq said.

“We need to learn from other countries in the region, such as Bangladesh, which has implemented more flexible pricing policies and attracted foreign investment in the pharmaceutical sector.”

Eli Lilly ceases operations in Pakistan

Haq noted that Pakistan imposes price controls on all 494 essential drugs, whereas India, Bangladesh, and Sri Lanka have more flexible structures. “We need to adopt a more nuanced approach to pricing — one that balances affordability with sustainability,” she said.

The current situation has negatively affected the availability and accessibility of innovative medicines for Pakistani patients, with limited choices, increased costs, and potential impact on quality.

Haq estimated that the potential loss due to MNCs exiting Pakistan is difficult to quantify but highlighted the potential for $5 billion in pharmaceutical exports and $1.5 billion in foreign direct investment if policies are adjusted.

“The future of foreign investment in Pakistan’s pharmaceutical sector is uncertain,” Haq said. “However, with the right policy reforms, we can create a more attractive business environment and attract foreign investment. We owe it to the people of Pakistan to ensure access to quality medicines and healthcare.”

Copyright Business Recorder, 2024

Comments

Comments are closed.

Tariq Qurashi Jul 22, 2024 09:15am
The Pharmaceutical sector is one of the Geese that has the potential to lay many golden eggs. Let us not kill this Golden Goose by overregulation, bureaucracy and red-tape. We need deep seated reforms
thumb_up Recommended (0)
Aamir Jul 22, 2024 11:59am
They are destroying every sector by such high taxes. Have already ruined real estate and now pharma. Next in line is Agriculture. Soon there will be nothing left and zero tax collection.
thumb_up Recommended (0)
Asaduddin Jul 22, 2024 12:28pm
Greed in pharmaceutical industries are bad. This affects poor masses. If deregulated, government should subsidize medicines so that it's affordable to the masses. Not everything is for exports.
thumb_up Recommended (0)
Ejaz Ahmad Jul 22, 2024 12:34pm
Government should subsidise if they heed the demands of these greedy sharks.
thumb_up Recommended (0)
Dr Rubiya Jul 22, 2024 12:43pm
Deregulation along with targeted subsidisation is the solution. BiSP data can be used for price mechanism of targeted subsidised deregulated medicines.
thumb_up Recommended (0)
Malyar Jul 22, 2024 05:03pm
Price cantrol policy is not an hardal for these companies because mnc sold the same drug on much lower price in india
thumb_up Recommended (0)